Pfizer Given Average Recommendation of “Buy” by Brokerages (NYSE:PFE)
Shares of Pfizer (NYSE:PFE) have been given an average rating of “Buy” by the eighteen analysts that are covering the company, Analyst Ratings Network reports. Seven investment analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $33.54.
Shares of Pfizer (NYSE:PFE) opened at 29.39 on Thursday. Pfizer has a 52 week low of $27.86 and a 52 week high of $32.96. The stock’s 50-day moving average is $29.33 and its 200-day moving average is $30.33. The company has a market cap of $186.4 billion and a price-to-earnings ratio of 18.45. Pfizer also was the recipient of a large decline in short interest in the month of August. As of August 15th, there was short interest totalling 69,502,226 shares, a decline of 4.3% from the July 31st total of 72,619,112 shares. Based on an average daily trading volume, of 24,441,395 shares, the days-to-cover ratio is presently 2.8 days. Approximately 1.1% of the company’s shares are sold short.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.01. The company had revenue of $12.80 billion for the quarter, compared to the consensus estimate of $12.49 billion. During the same quarter in the prior year, the company posted $0.56 earnings per share. The company’s quarterly revenue was down 1.5% on a year-over-year basis. Analysts expect that Pfizer will post $2.25 EPS for the current fiscal year.
PFE has been the subject of a number of recent research reports. Analysts at Deutsche Bank initiated coverage on shares of Pfizer in a research note on Wednesday, August 27th. They set a “buy” rating and a $34.00 price target on the stock. They noted that the move was a valuation call. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Pfizer in a research note on Friday, August 22nd. They now have a $30.00 price target on the stock. Finally, analysts at Credit Suisse cut their price target on shares of Pfizer from $35.00 to $34.00 in a research note on Thursday, August 14th.
Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.